Fake Medicine Being Sold At AIIMS Gate, Sample Failed

Rae Bareli : Counterfeit medicine are also being sold near the All India Institute of Medical Sciences (AIIMS). In the Testing by the Government Analytical Laboratory, Lucknow, a drug has been found to be spurious. In the testing, cefaxim salt was not found in the medicine, while the company claimed to have cefaxim in the medicine.

After the testing report, the Drug Inspector was asked to provide bills in relation to the medicine by giving notice to the shopkeeper by restricting the sale of the concerned batch of medicine.

Drug Inspector Shivendra Pratap Singh had drawn a sample of MISF-200 MB (batch number-CLB 45696) tablet from Shakuntala Medical Store near AIIMS in the month of February and sent it to the laboratory for testing. The expiry of this medicine is December 2024. The drug inspector said that the drug test report arrived on Monday. Cefixime and lactobacillus salt have been claimed in the medicine, but in the laboratory test, cefixime salt has not been found in the medicine. For this reason the drug has been declared spurious.

The DI said that by giving notice to the medical store operator, orders have been given to stop the sale of the medicine as well as to provide the bill regarding the medicine.

Other medical store operators have been instructed not to sell the medicine of the concerned batch. After completing the investigation of the case, a case will be filed in the ACJM court.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’